Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation

T. Tsai, S. Goodman, R. Saez, G. Schiller, D. Adkins, N. Callander, S. Wolff, C. O. Freytes

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Increasing numbers of patients have received autologous stem cell transplants (ASCT) for hematologic malignancies. Since only a fraction of these patients are cured, physicians are more frequently faced with the dilemma of how to manage relapse post-transplant. Potential advantages of allogeneic transplantation (alloBMT) over ASCT include lack of graft tumor contamination and presence of a graft-versus-tumor effect. For this reason, patients who relapse after ASCT are often considered candidates for allogeneic bone marrow transplantation. However, there is limited knowledge on the outcome of alloBMT in patients who relapse after ASCT. We retrospectively analyzed the outcome of 20 patients with malignant lymphoma (n = 14) and AML (n = 6) who underwent alloBMT after failing an ASCT. The median age was 30 (17-41) years and the interval from ASCT to alloBMT was 10.5 (2-25) months. Seventeen patients died between 0.3 to 11 months (median 2.0) after alloBMT, all due to BMT-related toxicities. Three patients remain alive and free of disease at 1.1, 1.2 and 2.5 years after alloBMT. Sixteen of the 18 evaluable patients (89%) developed grade II-IV acute GVHD. Patients undergoing alloBMT after ASCT have a very high treatment-related mortality and incidence of grade II-IV acute GVHD. Alternative treatments with salvage chemotherapy, radiation or investigational approaches should be considered in patients who relapse after ASCT.

Original languageEnglish (US)
Pages (from-to)859-863
Number of pages5
JournalBone Marrow Transplantation
Volume20
Issue number10
StatePublished - Nov 2 1997

Fingerprint

Autologous Transplantation
Homologous Transplantation
Bone Marrow Transplantation
Transplants
Recurrence
Stem Cells
Salvage Therapy
Hematologic Neoplasms
Lymphoma
Neoplasms
Radiation
Physicians
Drug Therapy

Keywords

  • BMT
  • Leukemia
  • Lymphoma
  • Relapse
  • Second transplant

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Tsai, T., Goodman, S., Saez, R., Schiller, G., Adkins, D., Callander, N., ... Freytes, C. O. (1997). Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplantation, 20(10), 859-863.

Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. / Tsai, T.; Goodman, S.; Saez, R.; Schiller, G.; Adkins, D.; Callander, N.; Wolff, S.; Freytes, C. O.

In: Bone Marrow Transplantation, Vol. 20, No. 10, 02.11.1997, p. 859-863.

Research output: Contribution to journalArticle

Tsai, T, Goodman, S, Saez, R, Schiller, G, Adkins, D, Callander, N, Wolff, S & Freytes, CO 1997, 'Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation', Bone Marrow Transplantation, vol. 20, no. 10, pp. 859-863.
Tsai T, Goodman S, Saez R, Schiller G, Adkins D, Callander N et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplantation. 1997 Nov 2;20(10):859-863.
Tsai, T. ; Goodman, S. ; Saez, R. ; Schiller, G. ; Adkins, D. ; Callander, N. ; Wolff, S. ; Freytes, C. O. / Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. In: Bone Marrow Transplantation. 1997 ; Vol. 20, No. 10. pp. 859-863.
@article{5714e22788b245f991ccc85e42313e84,
title = "Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation",
abstract = "Increasing numbers of patients have received autologous stem cell transplants (ASCT) for hematologic malignancies. Since only a fraction of these patients are cured, physicians are more frequently faced with the dilemma of how to manage relapse post-transplant. Potential advantages of allogeneic transplantation (alloBMT) over ASCT include lack of graft tumor contamination and presence of a graft-versus-tumor effect. For this reason, patients who relapse after ASCT are often considered candidates for allogeneic bone marrow transplantation. However, there is limited knowledge on the outcome of alloBMT in patients who relapse after ASCT. We retrospectively analyzed the outcome of 20 patients with malignant lymphoma (n = 14) and AML (n = 6) who underwent alloBMT after failing an ASCT. The median age was 30 (17-41) years and the interval from ASCT to alloBMT was 10.5 (2-25) months. Seventeen patients died between 0.3 to 11 months (median 2.0) after alloBMT, all due to BMT-related toxicities. Three patients remain alive and free of disease at 1.1, 1.2 and 2.5 years after alloBMT. Sixteen of the 18 evaluable patients (89{\%}) developed grade II-IV acute GVHD. Patients undergoing alloBMT after ASCT have a very high treatment-related mortality and incidence of grade II-IV acute GVHD. Alternative treatments with salvage chemotherapy, radiation or investigational approaches should be considered in patients who relapse after ASCT.",
keywords = "BMT, Leukemia, Lymphoma, Relapse, Second transplant",
author = "T. Tsai and S. Goodman and R. Saez and G. Schiller and D. Adkins and N. Callander and S. Wolff and Freytes, {C. O.}",
year = "1997",
month = "11",
day = "2",
language = "English (US)",
volume = "20",
pages = "859--863",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation

AU - Tsai, T.

AU - Goodman, S.

AU - Saez, R.

AU - Schiller, G.

AU - Adkins, D.

AU - Callander, N.

AU - Wolff, S.

AU - Freytes, C. O.

PY - 1997/11/2

Y1 - 1997/11/2

N2 - Increasing numbers of patients have received autologous stem cell transplants (ASCT) for hematologic malignancies. Since only a fraction of these patients are cured, physicians are more frequently faced with the dilemma of how to manage relapse post-transplant. Potential advantages of allogeneic transplantation (alloBMT) over ASCT include lack of graft tumor contamination and presence of a graft-versus-tumor effect. For this reason, patients who relapse after ASCT are often considered candidates for allogeneic bone marrow transplantation. However, there is limited knowledge on the outcome of alloBMT in patients who relapse after ASCT. We retrospectively analyzed the outcome of 20 patients with malignant lymphoma (n = 14) and AML (n = 6) who underwent alloBMT after failing an ASCT. The median age was 30 (17-41) years and the interval from ASCT to alloBMT was 10.5 (2-25) months. Seventeen patients died between 0.3 to 11 months (median 2.0) after alloBMT, all due to BMT-related toxicities. Three patients remain alive and free of disease at 1.1, 1.2 and 2.5 years after alloBMT. Sixteen of the 18 evaluable patients (89%) developed grade II-IV acute GVHD. Patients undergoing alloBMT after ASCT have a very high treatment-related mortality and incidence of grade II-IV acute GVHD. Alternative treatments with salvage chemotherapy, radiation or investigational approaches should be considered in patients who relapse after ASCT.

AB - Increasing numbers of patients have received autologous stem cell transplants (ASCT) for hematologic malignancies. Since only a fraction of these patients are cured, physicians are more frequently faced with the dilemma of how to manage relapse post-transplant. Potential advantages of allogeneic transplantation (alloBMT) over ASCT include lack of graft tumor contamination and presence of a graft-versus-tumor effect. For this reason, patients who relapse after ASCT are often considered candidates for allogeneic bone marrow transplantation. However, there is limited knowledge on the outcome of alloBMT in patients who relapse after ASCT. We retrospectively analyzed the outcome of 20 patients with malignant lymphoma (n = 14) and AML (n = 6) who underwent alloBMT after failing an ASCT. The median age was 30 (17-41) years and the interval from ASCT to alloBMT was 10.5 (2-25) months. Seventeen patients died between 0.3 to 11 months (median 2.0) after alloBMT, all due to BMT-related toxicities. Three patients remain alive and free of disease at 1.1, 1.2 and 2.5 years after alloBMT. Sixteen of the 18 evaluable patients (89%) developed grade II-IV acute GVHD. Patients undergoing alloBMT after ASCT have a very high treatment-related mortality and incidence of grade II-IV acute GVHD. Alternative treatments with salvage chemotherapy, radiation or investigational approaches should be considered in patients who relapse after ASCT.

KW - BMT

KW - Leukemia

KW - Lymphoma

KW - Relapse

KW - Second transplant

UR - http://www.scopus.com/inward/record.url?scp=0030730465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030730465&partnerID=8YFLogxK

M3 - Article

C2 - 9404927

AN - SCOPUS:0030730465

VL - 20

SP - 859

EP - 863

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 10

ER -